Related Experiment Videos
Coagulation inhibition for sepsis
1Department of Medicine, University of Minnesota Medical School, 480 Mayo Building, 420 Delaware St SE, Minneapolis, MN 55455, USA. keyxx001@umn.edu
Abstract:
Following on the heels of multiple failed clinical trials of adjunctive therapeutic agents in sepsis, the positive outcome of a recent phase III study using activated protein C (APC) has led to a renewed optimism in targeted biotherapies for this syndrome. A growing body of data (both preclinical and clinical) suggests that the protection against death afforded by APC cannot be solely explained by its antithrombotic activity but rather is likely explained by its associated anti-inflammatory and profibrinolytic effects. Although a recent phase III study failed to demonstrate any protective effect of another important antithrombotic molecule, antithrombin, it is premature to conclude that the benefit observed with APC is unique among inhibitors of the coagulation system. The result of a third phase III study examining the effect of tissue factor pathway inhibitor (TFPI) in sepsis is currently awaited, and the possibility that other antithrombotic agents--and combinations thereof--have a place in the therapeutic armamentarium will undoubtedly be the topic of future studies.
Insights
Activated protein C (APC) shows promise in sepsis treatment, offering benefits beyond anticoagulation. Further research into other coagulation inhibitors like antithrombin and tissue factor pathway inhibitor (TFPI) is ongoing.
Area of Science:
- Critical care medicine
- Hematology
- Pharmacology
Background:
- Sepsis treatment has seen numerous failed clinical trials for adjunctive therapies.
- Activated protein C (APC) demonstrated positive outcomes in a recent phase III trial, renewing optimism for targeted biotherapies.
Purpose of the Study:
- To evaluate the therapeutic potential of APC in sepsis.
- To explore the mechanisms of APC's protective effects beyond anticoagulation.
- To contextualize APC's efficacy within the broader landscape of coagulation system inhibitors.
Main Methods:
- Review of preclinical and clinical data for APC in sepsis.
- Analysis of a recent phase III clinical trial for APC.
- Consideration of data from trials involving antithrombin and tissue factor pathway inhibitor (TFPI).
Main Results:
- APC demonstrated a protective effect against mortality in sepsis.
- Evidence suggests APC's benefits stem from anti-inflammatory and profibrinolytic activities, not solely antithrombotic effects.
- A trial of antithrombin failed to show protective effects, highlighting the need for further investigation.
Conclusions:
- APC offers a potential targeted biotherapy for sepsis, with multifaceted mechanisms of action.
- The efficacy of APC suggests that other antithrombotic agents may also hold therapeutic value in sepsis.
- Future studies will likely investigate other coagulation inhibitors and combination therapies for sepsis management.